TSL2109 / Tasly - LARVOL DELTA

TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy (clinicaltrials.gov) - P1 | N=78 | Recruiting | Sponsor: Tasly Pharmaceutical Group Co., Ltd

New P1 trial • Breast Cancer • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • HER2 Breast Cancer • Oncology • Prostate Cancer • Solid Tumor • ER • HER-2 • PGR